phase ii trials have demonstrated a possible antitumoral activity in treating some solid tumors : malignant melanoma , renal cell carcinoma , ovarian adenocarcinoma , carcinoid tumor , superficial bladder cancer .
C0280100
solid tumors
C0025202
malignant melanoma